Jubilant Pharmova Limited (BOM:530019)
India · Delayed Price · Currency is INR 944.75
+5.85 (0.62%)
At close: Feb 12, 2026
Jubilant Pharmova Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 79,184 | 72,345 | 67,029 | 62,817 | 61,302 | 60,985 | |
Revenue Growth (YoY) | 12.09% | 7.93% | 6.71% | 2.47% | 0.52% | 2.05% |
Cost of Revenue | 27,758 | 25,357 | 23,513 | 20,816 | 14,880 | 15,360 |
Gross Profit | 51,426 | 46,988 | 43,516 | 42,001 | 46,422 | 45,625 |
Selling, General & Admin | 25,995 | 23,431 | 22,873 | 22,151 | 20,739 | 19,440 |
Other Operating Expenses | 12,789 | 11,837 | 11,593 | 12,011 | 13,621 | 11,509 |
Operating Expenses | 42,972 | 38,954 | 38,285 | 38,252 | 38,023 | 34,183 |
Operating Income | 8,454 | 8,034 | 5,231 | 3,749 | 8,398 | 11,443 |
Interest Expense | -1,886 | -2,209 | -2,564 | -1,686 | -1,382 | -1,734 |
Interest & Investment Income | 366 | 366 | 261 | 98 | 24.51 | 80.97 |
Earnings From Equity Investments | -4 | -5 | 511 | 123 | -99.83 | 112.52 |
Currency Exchange Gain (Loss) | 6 | 6 | -42 | 172 | -464.53 | -644.67 |
Other Non Operating Income (Expenses) | -24 | 2 | -5 | -83 | 14.45 | -40.22 |
EBT Excluding Unusual Items | 6,912 | 6,194 | 3,392 | 2,373 | 6,491 | 9,218 |
Gain (Loss) on Sale of Investments | 17 | 17 | 2 | -50 | 1.47 | 28.23 |
Gain (Loss) on Sale of Assets | - | - | - | -27 | -33.7 | -66.91 |
Asset Writedown | 3,595 | 3,595 | -1,689 | -1,450 | -153.83 | -255.81 |
Other Unusual Items | -4,083 | - | - | -568 | - | -212.31 |
Pretax Income | 6,441 | 9,806 | 1,705 | 278 | 6,304 | 8,711 |
Income Tax Expense | 2,146 | 1,443 | 978 | 927 | 2,174 | 2,972 |
Earnings From Continuing Operations | 4,295 | 8,363 | 727 | -649 | 4,130 | 5,739 |
Earnings From Discontinued Operations | - | - | - | - | - | 2,618 |
Net Income to Company | 4,295 | 8,363 | 727 | -649 | 4,130 | 8,356 |
Minority Interest in Earnings | 32 | 31 | 44 | 39 | 9.2 | 2.58 |
Net Income | 4,327 | 8,394 | 771 | -610 | 4,139 | 8,359 |
Net Income to Common | 4,327 | 8,394 | 771 | -610 | 4,139 | 8,359 |
Net Income Growth | -31.01% | 988.72% | - | - | -50.48% | -6.94% |
Shares Outstanding (Basic) | 159 | 158 | 159 | 159 | 159 | 159 |
Shares Outstanding (Diluted) | 159 | 159 | 159 | 159 | 159 | 159 |
Shares Change (YoY) | 0.06% | 0.01% | -0.18% | -0.02% | -0.06% | -0.01% |
EPS (Basic) | 27.30 | 52.98 | 4.86 | -3.83 | 26.01 | 52.48 |
EPS (Diluted) | 27.24 | 52.85 | 4.86 | -3.83 | 26.00 | 52.48 |
EPS Growth | -31.03% | 987.45% | - | - | -50.46% | -6.93% |
Free Cash Flow | - | -435 | 736 | -1,538 | 2,376 | 12,568 |
Free Cash Flow Per Share | - | -2.74 | 4.63 | -9.66 | 14.92 | 78.91 |
Dividend Per Share | - | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 |
Gross Margin | 64.94% | 64.95% | 64.92% | 66.86% | 75.73% | 74.81% |
Operating Margin | 10.68% | 11.11% | 7.80% | 5.97% | 13.70% | 18.76% |
Profit Margin | 5.46% | 11.60% | 1.15% | -0.97% | 6.75% | 13.71% |
Free Cash Flow Margin | - | -0.60% | 1.10% | -2.45% | 3.88% | 20.61% |
EBITDA | 10,703 | 10,477 | 7,933 | 6,463 | 10,663 | 14,676 |
EBITDA Margin | 13.52% | 14.48% | 11.83% | 10.29% | 17.39% | 24.07% |
D&A For EBITDA | 2,249 | 2,443 | 2,702 | 2,714 | 2,264 | 3,234 |
EBIT | 8,454 | 8,034 | 5,231 | 3,749 | 8,398 | 11,443 |
EBIT Margin | 10.68% | 11.11% | 7.80% | 5.97% | 13.70% | 18.76% |
Effective Tax Rate | 33.32% | 14.71% | 57.36% | 333.45% | 34.49% | 34.12% |
Revenue as Reported | 79,726 | 72,913 | 67,716 | 63,200 | 61,415 | 61,162 |
Advertising Expenses | - | 687 | 664 | 413 | 259.84 | 161.77 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.